Israeli scientists have figured out a way to cure cancer completely within a year. A task which sounds impossible, but according to Jerusalem Post the latest cure for cancer will not only be cheap and effective but will have no or minimal side effects.
Dan Aridor, chairman of the board of Accelerated Evolution Biotechnologies Ltd. (AEBi), a company founded in 2000 in the ITEK incubator in the Kiryat Weizmann Science Park in Ness Ziona, Israel said “We believe we will offer in a year’s time a complete cure for cancer”
The research involves a combination of cancer targeting peptides and a toxin that will specifically kill cancer cells. The research is developed by AEBi under the leadership of CEO Dr. Ilan Morad. The research involves the use of MuTaTo (multi-target toxin) which is a disruption technique of the highest order.
The researcher says the treatment is effective from day one and will last a duration of a few weeks. The solution provided will be both generic and personal and have no or minimal side effects at a much lower price than the treatments available right now in the market.
According to the Jerusalem Post, the anticancer drug is based on AEBi so-called SoAP technology which belongs to the phage display group of technologies. Here the scientists introduce DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria. This protein is displayed on the surface of the phage. These protein displaying phages can be used by researchers to screen for interactions with other proteins, DNA sequences, and small molecules.
The latest treatment with MuTaTo the cancer cells can be killed and the patients can stop treatment immediately after only a few weeks, unlike HIV and AIDS where they have to continue with a drug cocktail for the rest of their lives.
According to Aridor AEBi is n the process of writing patents on specific peptides which will be a large bank of targeting toxin peptides which are wholly owned and difficult to break.
Morad added – “The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used. Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.”
Morad suggested the MuTaTo cancer treatment will eventually be designed specifically for each person. Individual patients will be diagnosed in a lab via biopsy and treated accordingly. This will enable them to give them exactly the molecule cocktail needed to cure his disease he said.
Experiments have been successfully conducted by the company on mice, which were inhibited with human cancer cell growth and had no effect at all on healthy mice cells, in addition to several in-vitro trials( test- tube or culture dish).
The results from the various experiments conducted show they are consistent and repeatable.
- Latest Ransomware Makes $4 Million – Adopts “Big Game Hunting” Stratergy
- Walmart Introduces Floor Scrubbing Machines Built On BrainOS
- Microsoft Introduces New AI Powered Accessibility Feature For PowerPoint